Exhibit 99.1 Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti- tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types New paradigm for accelerated design and development of novel compounds, like ACR-2316, based on optimal intracellular pathway selectivity, uniquely enabl ...